Speculation is rife within Ranbaxy Laboratories that managing director and CEO D. S. Brar, who announced his resignation at a board meeting on Monday, may leave the company even before the end of his tenure on July 4, 2004 though he strongly denies such a move.
Highly placed sources in the company said differences over Brar’s plans with respect to the company’s interests in the US was one of the key reasons behind his resignation. When contacted, Brar ruled out the possibility of his leaving the company before the end of his tenure. “I have a task cut out for me and I will be very much there to complete my tenure.”
Sources said some top and senior level management changes are also expected in the new year now that Brar has decided to leave. Vice-president (legal) Vijaya Sampat has already put in her papers and is slated to join Bharti group as director (legal) on January 1. Sources in the company said while Brar is scheduled to continue as MD & CEO till July 4, his successor Brian Tempest will work effectively as the MD & CEO from January, even though he will be designated as joint MD and CEO-designate with effect from January 1.
Sources said some top and senior level managers may leave the company or may be replaced. Some of the managers who closely worked with Brar include Dr Rashmi Bharbhaiya (president, R&D); Vinod Dhawan (regional director — Asia Pacific), who had retired but got an extension till December 31, 2003; Sanjiv D. Kaul (V-P, corporate affairs, global licensing and allied business); Udai Upendra (V-P, global HR) and Rahul Goswami (V-P, strategic planning).